APNH.F Stock Overview
Manufactures and supplies specialty and branded pharmaceutical products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Aspen Pharmacare Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R12.25 |
| 52 Week High | R12.25 |
| 52 Week Low | R9.21 |
| Beta | 0.69 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -12.22% |
| 5 Year Change | 113.70% |
| Change since IPO | 210.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| APNH.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | 0.3% |
| 1Y | n/a | 10.8% | 31.1% |
Return vs Industry: Insufficient data to determine how APNH.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how APNH.F performed against the US Market.
Price Volatility
| APNH.F volatility | |
|---|---|
| APNH.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: APNH.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine APNH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1850 | 8,887 | Stephen Saad | www.aspenpharma.com |
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general, local, and regional anesthetic; low molecular weight heparin; regional and spinal anesthetic; and opioid analegesic under the Diprivan, Emla, Fraxiparine, Marcaine, Ultiva, and Xylocaine brand names.
Aspen Pharmacare Holdings Limited Fundamentals Summary
| APNH.F fundamental statistics | |
|---|---|
| Market cap | US$5.88b |
| Earnings (TTM) | US$270.85m |
| Revenue (TTM) | US$2.38b |
21.7x
P/E Ratio2.5x
P/S RatioIs APNH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APNH.F income statement (TTM) | |
|---|---|
| Revenue | R42.70b |
| Cost of Revenue | R23.49b |
| Gross Profit | R19.22b |
| Other Expenses | R14.35b |
| Earnings | R4.87b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 04, 2024
| Earnings per share (EPS) | 10.94 |
| Gross Margin | 45.00% |
| Net Profit Margin | 11.40% |
| Debt/Equity Ratio | 42.2% |
How did APNH.F perform over the long term?
See historical performance and comparison